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Skeletal muscle atrophy is caused by disruption in the homeostatic balance of muscle 2 
degeneration and regeneration under various pathophysiological conditions. We have 3 
previously reported that iron accumulation induces skeletal muscle atrophy via a 4 
ubiquitin ligase-dependent pathway. However, the potential effect of iron accumulation 5 
on muscle regeneration remains unclear. To examine the effect of iron accumulation on 6 
myogenesis, we used a mouse model with cardiotoxin (CTX)-induced muscle 7 
regeneration in vivo and C2C12 mice myoblast cells in vitro. In mice with iron overload, 8 
the skeletal muscles exhibited increased oxidative stress and decreased expression of 9 
satellite cell markers. Following CTX-induced muscle injury, these mice also displayed 10 
delayed muscle regeneration with a decrease in the size of regenerating myofibers, 11 
reduced expression of myoblast differentiation markers, and decreased phosphorylation 12 
of mitogen-activated protein kinase signaling pathways. In vitro, iron overload also 13 
suppressed the differentiation of C2C12 myoblast cells, but the suppression could be 14 
reversed by superoxide scavenging using tempol. Excess iron inhibits myogenesis via 15 
oxidative stress, leading to an imbalance in skeletal muscle homeostasis. 16 
 17 





Iron is an essential trace metal element. However, excess iron causes 21 
oxidative stress by catalyzing the production of highly toxic hydroxy-radicals via the 22 
Fenton reaction. Disorders, such as cardiomyopathy, hepatic failure, and diabetes, are 23 
induced by ectopic accumulation of excess iron in hereditary iron overload disorders 24 
(1). Moreover, increased iron content in the body can also be associated with many 25 
other diseases that do not fall under the domain of iron overload disorders. These 26 
include liver diseases (2), obesity (3), diabetes (4, 5), cardiovascular diseases (6, 7), and 27 
kidney diseases (8). These diseases are ameliorated by iron reduction, as shown by both 28 
clinical (9-11) and experimental studies (12-16) . 29 
Skeletal muscle wasting, also known as sarcopenia, is caused by aging (17) 30 
and chronic disorders, such as chronic heart failure (18), chronic kidney disease (CKD) 31 
(19), diabetes (20), and metabolic disease (21), which worsen quality of life and lead to 32 
morbidity or mortality (22). In terms of the relationship between skeletal muscle and 33 
tissue iron content indicated by serum ferritin (a marker of body iron store), high iron 34 
content is associated with a decrease in skeletal muscle mass in elderly women (23). 35 
The serum ferritin level is also higher in sarcopenic obese individuals (24). Skeletal 36 
muscle mass has been shown to decrease with increased iron accumulation (25-27) due 37 
to the alterations in iron metabolism in aged rats. Direct iron administration reduces 38 
skeletal muscle mass due to elevated oxidative stress (28), and skeletal muscle atrophy, 39 
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induced by excessive iron, involves E3 ubiquitin ligase action mediated by the 40 
inactivation of Akt-FOXO3a due to oxidative stress (29).  41 
Skeletal muscle is a highly regenerative organ in the body. The loss of muscle 42 
mass is induced by enhanced muscle degradation and by reduced muscle regeneration 43 
(30). In muscle regeneration, satellite cells are crucial in muscle growth and repair. In 44 
the process of regeneration upon muscle injury, the behavior of satellite cells is tightly 45 
regulated by several transcription factors during quiescence, proliferation, and 46 
differentiation. Pax-7 is expressed in adult quiescent satellite cells in mice (31) and 47 
human (32). In response to injury, satellite cells proliferate and activated cells express 48 
myogenic regulatory factors including myogenic differentiation 1 (MyoD), myogenic 49 
factor 5 (Myf5), and myogenin (Myog) (33), and Pax-7 is downregulated prior to 50 
terminal differentiation to myofibers (34). Notably, satellite cell dysfunction is seen in 51 
mouse models of aging (35, 36), diabetes (37-39), and CKD (40). and satellite cell 52 
numbers also decrease with age in humans (32, 41, 42).  53 
The balance between muscle regeneration and degradation is important for the 54 
maintenance of muscle mass. As described above, excess iron promotes skeletal muscle 55 
degradation via activation of E3 ubiquitin ligase (29). However, whether the 56 
regenerative potential of normal skeletal muscle is altered during iron overload induced 57 
muscle wasting is unknown. In the present study, we found that excess iron 58 
accumulation suppressed skeletal muscle differentiation by suppressing the 59 
mitogen-activated protein kinase (MAPK) signaling pathway, and that the delay in 60 
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skeletal muscle differentiation was a consequence of oxidative stress induced by excess 61 
iron.  62 
Material and methods  63 
Materials 64 
Saccharated ferric oxide (SFO) and cardiotoxin (CTX) were purchased from 65 
Nichi-Iko Pharmaceutical (Toyama, Japan) and A (St Louis, MO, USA), respectively. 66 
The following commercially available antibodies were used: anti-myosin heavy chain 67 
(Myh) 3 (same as embryonic Myh (eMyh)), anti-myogenin, anti-ferritin heavy chain 68 
(FTH), anti-ferritin light chain (FTL) (Santa Cruz Biotechnology, Inc., Dallas, TX), 69 
anti-phospho-p38MAPK (Thr180/Tyr182), anti-total p38MAPK, anti-phospho-p44/42 70 
MAPK (extracellular signal-regulated kinase 1/2, ERK1/2), anti-total p44/42 MAPK 71 
(Extracellular Signal-regulated Kinase (ERK) 1/2) (Cell Signaling Technology, 72 
Danvers, MA, USA), anti-Pax-7 (Developmental Studies Hybridoma Bank, Iowa City, 73 
IA, USA), and anti-α-tubulin (Merck KGaA, Darmstadt, Germany) as a protein loading 74 
control. Hydroxyphenyl fluorescein (HPF) was purchased from Goryo chemical 75 
(Sapporo, Japan). Deferoxamine (DFO) was purchased from Sigma-Aldrich (St. Louis, 76 
Missouri, USA). 77 
Animal preparation and procedures 78 
All experimental procedures for mice were performed in accordance with the 79 
guidelines of the Animal Research Committee of Tokushima University Graduate 80 
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School, and the protocol was approved by the Institutional Review Board of Tokushima 81 
University Graduate School for animal protection (Permit Number: 13095). The mice 82 
were randomly divided into two groups: vehicle group and iron treatment group. 83 
Seven-week-old male C57BL/6J mice were obtained from Nippon CLEA (Tokyo, 84 
Japan) and were maintained with ad libitum access to water and food (Type NMF; 85 
Oriental Yeast, Tokyo, Japan). After 1 week of acclimation, to prepare a mouse model 86 
of iron overload, mice were treated once a week with intraperitoneal SFO (2 mg/200 87 
μl/25 g mouse) or with the same volume of vehicle for four consecutive weeks (43). 88 
Aged C57BL/6J mice were 2 years old. Control young mice were 2 months old. In the 89 
type 2 diabetic mouse model, 8-week-old BKS-background db/db mice (diabetes) and 90 
heterozygous db/m mice (non-diabetes) were purchased from Nippon CLEA Japan, Inc. 91 
(Tokyo, Japan). Adenine-induced CKD model mice were prepared as previously 92 
described (44). 93 
CTX-induced muscle injury model 94 
A 50 µl volume of 10 µM CTX or an equal volume of phosphate buffered 95 
saline (PBS) was injected into the gastrocnemius (GA) muscles using an insulin syringe 96 
as described previously (45). On day 0, 3, 7, and 14 after CTX injection, the mice were 97 
euthanized by intraperitoneally injecting an overdose of pentobarbital, and GA muscles 98 
were removed and stored at −80°C until further use. 99 
Cell culture  100 
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We used C2C12 myoblast cells to investigate the effect of excess iron on 101 
skeletal muscle differentiation as described previously (29). The cells were grown to 102 
sub-confluence for approximately 24–48 h, and incubated with either vehicle or iron 103 
sulphate (FeSO4) for 24 h. The culture medium was replaced with a differentiation 104 
medium (DMEM) containing 2% horse serum, and incubated for the indicated 105 
durations. In some experiments, the cells were pre-treated with 100 μM tempol and 50 106 
μM DFO for 1 h before stimulation with iron. The treatment protocol of FeSO4 and 107 
tempol was determined in our previous study (29). We performed 3 to 6 well replicates 108 
per experiment and repeated each experiment at least 2 times. C2C12 myoblast cells 109 
were used until the 5th to 7th passages. 110 
RNA extraction and evaluation of mRNA expression levels 111 
The methods of RNA extraction, cDNA synthesis, and quantitative RT-PCR 112 
have been previously described (46). In brief, the tissues were homogenized with the 113 
Minilys beads-based homogenizer (Bertin Instruments, Montigny-le-Bretonneux, 114 
France) in RNAiso reagent (Takara Bio, Otsu, Japan). RNA extraction and cDNA 115 
synthesis were performed according to the manufacturer’s instructions (PrimeScript RT 116 
reagent kit with gDNA Eraser (Perfect Real Time), Takara Bio). Quantitative RT-PCR 117 
was performed using the CFX Connect Real-Time PCR Detection System (Bio-Rad 118 
Laboratories, Hercules, CA, USA) with THUNDERBIRD® SYBR® qPCR Mix 119 
(TOYOBO Co., Ltd., Osaka, Japan). The primer sets used were: 5 ′ - 120 
GACTCCGGATGTGGAGAAAA-3′ and 5′-GAGCACTCGGCTAATCGAAC -3121 
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′  for Pax-7, 5 ′ - AGTGAATGAGGCTTCGAGA-3 ′  and 5 ′122 
-CAGGATCTCCACCTTGGGTA-3 ′  for MyoD, 5 ′ - 123 
AGACGCCTGAAGAAGGTGAC-3′ and 5′-ACCTTGGGGAGTCTCTTCAA-3′ 124 
for Myf5, 5 ′ - CACGATGGACGTAAGGGAGT -3 ′  and 5 ′ - 125 
CCAGATGGACGTAAGGGAGT-3 ′  for Myogenin, 5 ′ - 126 
AGAGTCTGTCAAGGCCCTGA-3′ and 5′- CAGCCTGCCTCTTGTAGGAC-3′ 127 
for Myh3 (embryonic Myh),  5′-GAGCGGAGAGTACTGGATCG-3′  and 5′128 
-GTTCGGGCTGATGTACCAGT-3′ for collagen type I alpha 1 chain (Col1a1), 5′129 
-GTGTTCAAGGTGGCAAAGGT-3′ and 5′-GACCGAATTCACCAGGAAGA-3130 
′  for collagen type I alpha 2 chain (Col1a2), 5 ′131 
-ACCAAAAGGTGATGCTGGAC-3′  and 5′ -GACCTCGTGCTCCAGTTAGC-3132 
′  for collagen type III alpha 1 chain (Col3a1), 5 ′133 
-TGAGTGGCTGTCTTTTGACG-3′ and 5′-AGCCCTGTATTCCGTCTCCT-3′ 134 
for transforming growth factor-beta 1 (Tgf-1), 5 ′135 
-CTGTAACCGGATGGCAAACT-3′ and 5′-CTGTACCCACATGGCTGATG-3′ 136 
for F4/80, and 5 ′ -GCTCCAAGCAGATGCAGCA-3 ′  and 5 ′137 
-CCGGATGTGAGGCAGCAG-3′ for 36B4 (internal control). The expression levels 138 
of all target genes were normalized using 36B4 expression, and the values were 139 
compared to the control group in terms of relative fold changes. 140 
Protein extraction and western blot analysis  141 
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Protein extraction and western blotting were performed as previously 142 
described (46). The tissue or cell samples were homogenized or sonicated in a protein 143 
lysis buffer containing inhibitors of proteinase and phosphatase, and the proteins were 144 
extracted. The extracted proteins were boiled for 5 min in Laemmli sample buffer and 145 
used for western blotting. The detected immune-reactive bands were quantified by 146 
densitometric analysis using Image J (version 1.38) software (National Institutes of 147 
Health, Bethesda, MD, USA) as described previously (47). Phosphorylation specific 148 
signals are normalized against levels of total target protein, and protein expression is 149 
normalized using tubulin as an internal loading control. 150 
Histological analysis 151 
GA muscles were fixed overnight in 4% paraformaldehyde at 4°C and 152 
embedded in paraffin. Sections 3 µm in thickness were prepared and stained with 153 
hematoxylin-eosin to measure the area of muscle fiber. Area measurements of at least 154 
100 fibers were obtained for each animal from 10 randomly selected fields in five 155 
different sections. Muscle fiber area was quantified using Image J (version 1.38) 156 
software. The regenerating myofibers were indicated as myofibers with centralized 157 
nuclei. Picrosirius red staining was used for evaluating skeletal muscle fibrosis as 158 
previously described (48).  159 
Fusion index  160 
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 Forty-eight hours after the initiation of muscle differentiation, C2C12 cells 161 
were fixed with 4% paraformaldehyde for 10 min and stained with anti-Myh3 overnight 162 
at 4°C and mounted using mounting medium 4′,6-diamidino-2-phenylindole (DAPI, 163 
VECTASHIELD; Vector Laboratories, Burlingame, CA, USA). Five different fields per 164 
well were randomly selected and the number of nuclei in each myotube and the total 165 
number of nuclei in cells were counted in each field. The fusion index was calculated as 166 
the percentage of the total number of nuclei in Myh-positive cells from the total number 167 
of nuclei counted in the field. 168 
In situ superoxide detection 169 
Superoxide production in the skeletal muscle was detected by the 170 
dihydroethidium (DHE) staining method as described previously (29). Non-fixed frozen 171 
tissue sections were incubated with DHE in PBS (10 μM) in a dark, humidified 172 
container at room temperature for 30 min and then observed using a fluorescence 173 
microscope.  174 
In situ detection of labile ferrous iron and hydroxyl radicals 175 
Labile ferrous iron and hydroxyl radicals were detected by RhoNox-1 (49) 176 
and HPF, respectively. In brief, the frozen sections were fixed in 10% neutral 177 
formaldehyde for 1 min, washed with HBSS, and incubated with 5 μM RhoNox-1 and 5 178 
μM HPF in a dark, humidified container at room temperature for 30 min. After washing, 179 
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the section was observed using fluorescence microscopy (46). RhoNox-1 was 180 
synthesized according to the literature procedure (49). 181 
TBARS assay 182 
A thiobarbituric acid reactive substance (TBARS) assay was used to measure 183 
malondialdehyde (MDA) concentration in skeletal muscles as previously described 184 
(13). The suspension of homogenized muscle tissue that was not centrifuged was used 185 
for the assay.  186 
Measurement of oxidative stress in C2C12 myoblast cells 187 
Intracellular reactive oxidative species were detected and quantified using 2′188 
, 7′-dichlorofluorescin diacetate (DCFH-DA; Sigma-Aldrich) as described previously 189 
(46).  190 
Cell viability assay 191 
Cell proliferation was accessed using a CellTiter 96 AQueous non-radioactive 192 
cell proliferation assay kit (Promega KK, Tokyo, Japan) (46). Cytotoxicity was 193 
evaluated using a Cytotoxicity LDH Assay Kit-WST (DOJINDO LABORATORIES, 194 
Kumamoto, Japan) according to the manufacturer’s instructions. Briefly, C2C12 195 
myoblast cells were seeded in 96-well plates at a cell concentration of 1 × 10
4
 cells per 196 
well and incubated for 24 h. When the cell growth was sub-confluent, FeSO4 was added 197 
and the cells were cultured in DMEM with or without fetal bovine serum (FBS) for 24 198 
h. The proliferation or cytotoxicity of cells was assessed with MTS assay or LDH assay 199 
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by measuring the absorbance at 490 nm using an iMARK microplate reader (Bio-Rad 200 
Laboratories).  201 
Quantification of iron content 202 
Iron content of tissues or cells was measured using an iron assay kit according 203 
to the manufacturer’s instructions (Metallo assay LS, Metallogenics, Chiba, Japan) as 204 
described previously (29). Iron concentration was evaluated using tissue-weight or 205 
protein concentration and expressed as μg Fe per g of wet tissue or μg Fe per protein 206 
concentration. 207 
Measurement of p38MAPK activity 208 
The activity of p38MAPK was measured using a commercially available kit 209 
according to the manufacturer’s instructions (CycLex p38 Kinase Assay/Inhibitor 210 
Screening Kit, MEDICAL and BIOLOGICAL LABORATORIES Co., Ltd., Nagoya, 211 
Japan). 212 
Statistical analysis 213 
Data are presented as mean ± standard deviation (mean ± SD). Mann–Whitney 214 
U test was used for comparisons between the two groups. For comparisons between 215 
more than two groups, the statistical significance of each difference was evaluated using 216 
the Kruskal–Wallis test. Statistical significance was indicated by P < 0.05. 217 
Results 218 
Iron content of skeletal muscle in mouse models of aging, diabetes, and CKD 219 
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  Skeletal muscle regeneration is suppressed during muscle wasting due to 220 
aging in humans (41), in addition to diabetes (37) and CKD (40) in mice. We first 221 
evaluated iron accumulation in skeletal muscle under the above conditions using a 222 
mouse model involving aged mice (2-years-of-age), db/db mice (type 2 diabetic model), 223 
and CKD mice (adenine-induction), respectively. Iron content (Figure 1A), as well as 224 
FTH and FTL protein expression (Supplementary figure), were elevated in skeletal 225 
muscle with aging, diabetes, and CKD. Similar to iron content, oxidative stress was also 226 
increased in skeletal muscles with aging, diabetes, and CKD (Figure 1B). In terms of 227 
mRNA expression of satellite cell markers, Pax-7, MyoD, and Myf5 were significantly 228 
reduced in skeletal muscles of mice with diabetes and CKD. Aged mice displayed 229 
reduced mRNA expression of Pax-7 and Myf5, but not MyoD, in skeletal muscles 230 
(Figure 1C). Iron accumulation in skeletal muscle might cause the decline of satellite 231 
cells by increasing oxidative stress. Therefore, iron is a potential problem for impaired 232 
myogenesis in aging, diabetes, and CKD. 233 
Effect of iron overload on skeletal muscle 234 
 To evaluate the effect of excess iron on muscle regeneration, we used mice 235 
with iron overload. The iron overload model showed that there were no differences in 236 
body weight and skeletal muscle weight between vehicle- and iron-treated mice (Table. 237 
1). Iron content as well as the protein expression of FTH and FTL were increased in 238 
mice with iron overload (Figures 2A and B). Oxidative stress markers, such as DHE 239 
intensity and TBARS concentration, were increased in skeletal muscles of mice with 240 
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iron overload (Figures 2C and D). The mRNA expression of satellite cell markers Pax-7 241 
and MyoD was significantly reduced in skeletal muscles of mice with iron overload 242 
(Figure 2E). Similarly, the number of Pax-7 positive cells was reduced in skeletal 243 
muscles of iron-treated mice (Figure 2F). However, there were no differences in muscle 244 
fiber area as well as mRNA expression of atrogin-1 and MuRF1 between 245 
vehicle-treated mice and iron-treated mice (Figure 2G and H). 246 
Suppressive action of iron accumulation on skeletal muscle regeneration after 247 
CTX-induced injury 248 
To examine the effect of iron accumulation on skeletal muscle regeneration, CTX was 249 
injected in the skeletal muscles of mice. The mRNA expression of myogenic 250 
transcription factors myogenin and Myh3 were upregulated in muscles after CTX injury. 251 
However, their mRNA expression was downregulated in mice with iron overload 252 
(Figure 3A). Histological analysis revealed that mice with iron overload showed 253 
reduced number of regenerated muscle fibers with centralized nuclei as well as muscle 254 
fiber area after CTX injury on day 7 and day 15 compared to control mice (Figures 3B 255 
and C). In addition, fibrosis-related genes (Col1a1, Col1a2, Col3a1, and Tgf-1 256 
mRNA) were highly expressed in muscle of the iron-treated group at day3 or 7 and later 257 
after CTX injury (Figure 3D). Collagen deposition was increased in CTX-injured 258 
muscle at day 15 of iron overload as visualized in histology with picrosirius red staining. 259 
On the contrary, no differences in the expression of the macrophage marker F4/80 were 260 
observed in skeletal muscle between the vehicle- and iron-treated groups (data not 261 
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shown). The p38MAPK-dependent pathway plays a pivotal role in the activation of 262 
myogenic differentiation (50). Diabetic and CKD mice, not aged mice, showed the 263 
reduced phosphorylation of p38MAPK and ERK1/2 (Figure 1D and E). 264 
Phosphorylation of p38MAPK was upregulated in skeletal muscles after CTX injury on 265 
day 3, day 7 and day 14, which was suppressed by iron overload. Similar to p38MAPK, 266 
the degree of ERK1/2 phosphorylation was also lower on day 3 and 7 in CTX-injured 267 
muscle of mice with iron overload (Figure 3F).  268 
Inhibitory action of iron on C2C12 myoblast differentiation 269 
 To examine the mechanism of inhibitory effect of iron on skeletal muscle 270 
regeneration, we used C2C12 myoblast cells. The proliferative activity of these cells 271 
was prevented by iron treatment in the presence or absence of serum in the culture 272 
media. We also tested cytotoxicity of iron by LDH assay, and iron treatment increased 273 
LDH release independent of the presence or absence of serum in the culture media 274 
(Figure 4A). C2C12 myoblast cells were differentiated with an increase in Myh and 275 
myogenin mRNA expression after transfer of cells to differentiation media, which 276 
inhibited by concomitant treatment with iron (Figures 4B). The fusion index of 277 
myotubes was also reduced by iron treatment (Figure 4C). p38MAPK phosphorylation 278 
was significantly higher in C2C12 myoblast cells treated with iron before differentiation. 279 
However, the increase in p38MAPK phosphorylation was even lower 5 and 10 min after 280 
transfer to the differentiation media in iron-loaded C2C12 myoblast cells compared with 281 
vehicle-loaded cells. ERK1/2 phosphorylation was also higher in C2C12 myoblast cells 282 
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at 10, 15, and 30 min after transfer to the differentiation media, which was suppressed 283 
in iron-loaded culture media beforehand (Figure 4D). Similar to p38MAPK 284 
phosphorylation, p38MAPK activity was increased after the changing to differentiation 285 
media. This increase was lowered by iron treatment (Figure 5F). 286 
Involvement of oxidative stress in iron-mediated suppression of C2C12 myoblast 287 
differentiation 288 
 In C2C12 myoblast cells, oxidative stress was induced by iron overload, 289 
which was later suppressed by the superoxide scavenger tempol (Figure 5B). The iron 290 
content was also increased by iron treatment. However, tempol did not change the 291 
increased iron content (Figure 5A). Iron-induced inhibition of C2C12 myoblast 292 
differentiation, which lead to a reduction in mRNA expression of myogenin and Myh as 293 
well as decrease in fusion index, was restored by tempol pre-treatment (Figures 5C and 294 
D). Tempol partially ameliorated the reduced phosphorylation of p38MAPK and 295 
ERK1/2, which was inhibited by iron treatment 5 min or more after transfer to the 296 
differentiation medium (Figure 5E). In addition, tempol reversed the reduced 297 
p38MAPK activity with iron treatment 5 min after the change to differentiation medium 298 
(Figure 5G). In addition, DFO, an iron chelator, partly ameliorated iron-mediated 299 




Iron accumulation has a harmful effect on myogenesis due to oxidative stress, 302 
causing imbalance in skeletal muscle homeostasis. Presently, the suppression of skeletal 303 
muscle regeneration due to iron overload, the increment of oxidative stress in a mouse 304 
model of CTX injury, and the inhibitory action of iron on muscle differentiation were 305 
all recovered by tempol in vitro.  306 
 Skeletal muscle mass is determined and regulated by the coordinated balance 307 
between muscle degradation and regeneration. Disruption of this balance leads to a 308 
decrease in skeletal muscle mass, which is known as sarcopenia. Excess iron causes 309 
skeletal muscle atrophy by inducing protein degradation due to oxidative stress (28, 29). 310 
In the present study, excess iron also impaired myogenesis due to oxidative stress. Our 311 
findings suggested that iron plays a pivotal role in the loss of skeletal muscle mass 312 
through its anti-myogenesis properties. 313 
 Mice with excess iron showed reduced mRNA expression of the satellite cell 314 
markers Pax-7 and MyoD in skeletal muscle under basal conditions. The activation of 315 
satellite cell markers is an important event during muscle repair and regeneration in 316 
mice (51, 52). Conversely, inactivation of these markers occurs with age or disease. The 317 
number and function of satellite cell markers are also reduced and impaired in muscles 318 
of mice with advancing age (35, 36, 53). The expression of Pax-7 and MyoD is 319 
decreased in skeletal muscles of mice with CKD (40) and diabetes (37-39). In humans, 320 
satellite cell numbers and Pax-7 expression decrease in skeletal muscle with aging 321 
relative to those during youth (41, 42), and myogenic potential of satellite cells is 322 
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compromised in aging human muscle (54). Moreover, there is a decline in the capacity 323 
of muscle regeneration with increasing age in both mice and humans (55-57), 324 
suggesting skeletal muscle loss mediated by the reduction of myogenesis. We found 325 
that iron concentration was elevated and that satellite cell markers were reduced in 326 
skeletal muscles in mouse models of aging, CKD, and diabetes. Oxidative stress 327 
influences both the function and proliferation of satellite cells (58). Oxidative stress was 328 
increased in the skeletal muscle of the mouse models. Therefore, iron accumulation 329 
might augment oxidative stress and promote the decline of both satellite cell number 330 
and function, resulting in impaired muscle regeneration. Satellite cells are generally 331 
thought to be essential during muscle regeneration. A recent study has shown that 332 
expression of Pax-7 in satellite cells is lower, and the exercise-induced satellite cell 333 
response is blunted in skeletal muscle of old mice (32). On the other hand, satellite cell 334 
numbers do not decline in human muscle with aging (59), and there is no difference in 335 
the proliferative response of satellite cells between children and adults (58). There is no 336 
difference in satellite cell numbers between young and aged mice although an 337 
age-related decline in myoblast generation is seen in response to injury (60). Thus, 338 
studies of age-related decreases in satellite cell number and function have to date 339 
yielded contradictory results. Therefore, further studies are necessary for clarifying the 340 
role of satellite cells in impaired muscle regeneration and muscle loss during aging 341 
conditions, as well as in disease states such as diabetes and CKD. 342 
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CTX-injured muscle showed increased Tgf-1, Col1 and Col3 mRNA and 343 
collagen deposition, and these were higher in mice with iron overload, resulting in the 344 
promotion of excessive fibrosis. Similar to skeletal muscle, iron causes tissue fibrosis in 345 
cardiovascular organs (15, 61), kidney (14, 62), and liver (63) in mouse disease models. 346 
The interaction between fibroblasts and satellite cells is important in the regulation of 347 
myogenesis (64). Abnormal extracellular matrix deposition and fibrosis are known to 348 
impair muscle regeneration after acute injury (65, 66). Deletion of satellite cells also 349 
enhances muscle fibrosis after CTX-injury (64). Therefore, increased fibrosis, as well as 350 
reduced satellite cell numbers, might lead to compromised myogenesis after CTX injury 351 
under iron overload. 352 
 CTX-injured muscle regeneration has been widely accepted as a valid means 353 
of investigating the mechanism of skeletal muscle regeneration and differentiation (67). 354 
Generally, the expression of myogenin and Myh are upregulated and regenerative 355 
muscle fibers with centered nuclei are seen during muscle regeneration after CTX injury 356 
(40, 68). In the present study, iron-treated mice displayed suppressed upregulation of 357 
myogenin and Myh3 mRNA expression and the regenerative muscle fibers with central 358 
nuclei were reduced in injured muscle with CTX compared to vehicle-treated mice. This 359 
indicates the involvement of iron in impaired muscle regeneration. In addition, the 360 
phosphorylated levels of p38MAPK and ERK1/2 were increased in CTX-injured 361 
muscle. However, the increase in phosphorylated levels was also lowered in skeletal 362 
muscles of mice treated with excess iron. The p38MAPK signaling pathway is crucial in 363 
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regulating skeletal muscle gene expression at different stages of the myogenic process 364 
(69). p38MAPK promotes skeletal muscle differentiation via activation of the MEF2C 365 
transcription factor (50, 70). Thus, p38MAPK activation is essential for skeletal muscle 366 
differentiation and regeneration. In the light of ERK1/2 action on skeletal muscle 367 
differentiation, ERK1/2 activation also seems to promote skeletal muscle differentiation 368 
in a similar manner along with the p38MAPK signaling pathway. Inhibition of ERK1/2 369 
signaling suppresses multinucleated myotube formation and decreases the expression of 370 
muscle-specific genes (MyoD and myogenin) in myoblasts after the induction of 371 
differentiation (70-72). However, ERK1/2 is reportedly required for myoblast 372 
proliferation, but not for differentiation (73, 74). Thus, the role of the ERK1/2 pathway 373 
on skeletal muscle differentiation is still controversial and further research is needed to 374 
clarify this aspect. 375 
In the present study, excess iron increased ferrous iron and reactive oxygen 376 
species (ROS) abundance in skeletal muscle, suggesting the occurrence of the Fenton 377 
reaction under iron overload. C2C12 myoblast differentiation was impaired under iron 378 
overload conditions, and the free radical scavenger tempol ameliorated iron-mediated 379 
reduction of myoblast differentiation and MAPK activity, indicating the involvement of 380 
excess iron-mediated oxidative stress in impaired muscle differentiation via inactivation 381 
of the p38MAPK and ERK1/2 signaling pathways. We have previously shown that iron 382 
reduces Akt-FOXO3a phosphorylation and that this phosphorylation is prevented by 383 
tempol (29). Therefore, iron-mediated oxidative stress might be involved in the 384 
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suppression of the aforementioned kinase pathway. Previous studies have shown that 385 
oxidative stress induced by hydrogen peroxide or creatinine directly impairs muscle 386 
differentiation in C2C12 myoblast cells (75-77). Tumor necrosis factor-alpha-induced 387 
oxidative stress is involved in impaired muscle differentiation in tumor-bearing mice 388 
(78). Thus, ROS can generally cause inhibition of myogenic differentiation (75, 76, 79), 389 
and this action cannot be attributed solely to increased cell death (77). ROS can increase 390 
nuclear factor-kappa B (NF-B) activity (75), which inhibits skeletal muscle 391 
differentiation (80, 81). Taken together, iron overload might promote ROS-mediated 392 
impaired myogenesis.  393 
On the other hand, oxidative stress also plays an important signaling role in 394 
skeletal muscle adaptation (82). Contrary to our findings, oxidative stress induced by 395 
hydrogen peroxide activates the p38MAPK and ERK1/2 pathways through NF-B 396 
transactivation in skeletal myoblasts (83). Therefore, the effect of oxidative stress on 397 
myogenesis has dual physiological and pathological aspects and is controversial (84). 398 
More research is necessary to further elucidate the inhibitory mechanisms of iron on 399 
myogenesis. 400 
Iron deficiency is an acknowledged concern, and functional foods amended 401 
with iron are commercially available to prevent iron deficiency. However, as previously 402 
mentioned, the iron content in the human body increases with age and in diseases, 403 
including diabetes and CKD, indicating increased iron content in skeletal muscle. The 404 
level of iron intake is important. Excess iron intake impairs regeneration of skeletal 405 
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muscle and can induce muscle atrophy. Muscle atrophy and degradation in the presence 406 
of excess iron also involves the oxidative stress-ubiquitin ligase E3 pathway (29). Thus, 407 
iron deficiency and excess can be detrimental. 408 
In conclusion, iron overload affects skeletal muscle differentiation, possibly 409 
through oxidative stress-dependent inhibition of the p38 MAPK and ERK1/2 signaling 410 
pathways. This finding suggests a crucial role of iron in muscle regeneration, and 411 
clarifies the underlying mechanisms of skeletal muscle homeostasis.  412 
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Fig 1. Iron content, oxidative stress, MAPKs phosphorylation, and satellite cell markers 
in mice models of aging, diabetes, and chronic kidney disease (CKD)  
(A) Iron content of skeletal muscle in 2-month-old versus 2-year-old mice, db/m mice 
versus db/db mice, and control mice versus CKD mice. Values are expressed as mean ± 
SD. *P < 0.05 (in each paired comparison); n = 8 in each group. (B) Left panel: 
Representative images of DHE staining of skeletal muscle of 2-month-old versus 
2-year-old mice, db/m mice versus db/db mice, and control mice versus CKD mice with 
negative controls in each mouse (NC: negative control). Right panel: Quantitative 
analysis of relative fluorescence intensity. Values are expressed as mean ± SD; n = 5 in 
each group. *P < 0.05 (in each paired comparison). (C) mRNA expression of the 
satellite cell markers Pax-7, MyoD, and Myf5 in skeletal muscle of 2-month-old versus 
2-year-old mice, db/m mice versus db/db mice, and control mice versus CKD mice.  
Values are expressed as mean ± SD; n = 5 in each group. *P < 0.05 (in each paired 
comparison). Phosphorylation of (D) p38MAPK and (E) ERK1/2 in skeletal muscle of 
2-month-old versus 2-year-old mice, db/m mice versus db/db mice, and control mice 
versus CKD mice. Upper panel: representative protein expression levels of 
phosphorylated p38MAPK, total p38MAPK, phosphorylated ERK1/2, total ERK1/2, 
and tubulin. Lower panels: semi-quantitative densitometry analysis of p38MAPK and 
ERK1/2 phosphorylation. Values are expressed as mean ± SD. *P < 0.05 (in each 




Fig 2. Iron status, oxidative stress, MAPK phosphorylation, and satellite cell marker 
levels, and histology of skeletal muscle at basal conditions in mice with vehicle 
treatment or iron overload. 
(A) Iron concentration in skeletal muscles. Values are expressed as mean ± SD. **P < 
0.01; n = 6–12 in each group. (B) Protein expression of H-ferritin (FTH) and L-ferritin 
(FTL) in skeletal muscle. Upper panel: representative protein expression levels of FTH, 
FTL, and tubulin. Lower panels: semi-quantitative densitometry analysis of FTH and 
FTL expression. Values are expressed as mean ± SD. **P < 0.01; n = 6–9 in each 
group. (C) Left panel: Representative images of DHE staining of skeletal muscle with 
negative controls in each mouse. Right panel: Quantitative analysis of relative 
fluorescence intensity. Values are expressed as mean ± SD; n = 6–9 in each group. **P 
< 0.01 (vs. vehicle). (D) Malondialdehyde concentration in skeletal muscle. Values are 
expressed as mean ± SD; n = 11–12 in each group. *P < 0.05. (E) mRNA expression of 
satellite cell markers in skeletal muscle. Values are expressed as mean ± SD; n = 10–14 
in each group. **P < 0.01 (vs. vehicle). (F) Left panels: Representative images of Pax-7 
(red), 4′,6-diamidino-2-phenylindole (DAPI, blue), and merged (purple) with negative 
control in gastrocnemius muscle of vehicle-treated and iron-treated mice. Right panel: 
Quantitative analysis of Pax-7 positive cells. Values are expressed as mean ± SD; n = 
5-6 in each group. *P < 0.05 (vs. vehicle). (G) Left panel: Representative images of 
skeletal muscle with or without iron load. Right panel: The mean area of muscle fibers. 
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Values are expressed as mean ± SD. (H) mRNA expression of atrogen-1 and MuRF1 in 
skeletal muscle. Values are expressed as mean ± SD; n = 7 in each group. (I) Left 
panels: Representative images of RhoNox-1 (red), hydroxyphenyl fluorescein (HPF, 
green), 4′ ,6-diamidino-2-phenylindole (DAPI, blue), and merged (orange) with 
negative control in gastrocnemius muscle of vehicle-treated and iron-treated mice. Right 
panel: Semi-quantitative analysis of RhoNox-1 and HPF fluorescence intensity. Values 
are expressed as mean ± SD; n = 5 in each group. *P < 0.05 (vs. vehicle). 
Fig 3. Regeneration of skeletal muscle after cardiotoxin (CTX)-induced injury in mice 
with or without iron treatment  
(A) The effect of iron overload on the changes in myogenin and Myh3(eMyh) mRNA 
expression in skeletal muscle after CTX injection. Values are expressed as mean ± SD. 
*P < 0.05, **P < 0.01 (vs. vehicle at same day); n = 6-14 in each group. (B) Left; 
Representative images of CTX-induced muscle injury at day 7 with or without iron 
loading. Right; The percentage of regenerating myofibers with centralized nuclei, the 
mean area of muscle fibers, and the distribution of myofiber areas in skeletal muscles 7 
days after CTX injection. Values are expressed as mean ± SD. ** P < 0.01 (vs. vehicle); 
n = 6–14 in each group. (C) Left; Representative images of CTX-induced muscle injury 
at day 15 with or without iron loading. Right; Percentage of regenerating myofibers 
with centralized nuclei, the mean area of muscle fibers, and the distribution of myofiber 
areas in skeletal muscles at 15 days after CTX injection. Values are expressed as mean 
± SD. ** P < 0.01 (vs. vehicle); n = 5-6 in each group. (D) The effect of iron overload 
 
 36 
on changes in Collagen 1a1 (Col1a1), Collagen 1a2 (Col1a2), and Collagen III 
(Col3a1), and Transforming growth factor beta-1 (Tgf-1) mRNA expression in 
skeletal muscle after CTX injection. Values are expressed as mean ± SD. *P < 0.05 (vs. 
vehicle at same day); n = 6 in each group. (E) Histological analysis of fibrosis in 
skeletal muscle at day 15 after CTX injury. Left; Representative images of picrosirius 
red staining in CTX-induced muscle injury at day 15 with or without iron loading. 
Right; Percentage of fibrosis fraction in skeletal muscles at 15 days after CTX injury. 
Values are expressed as mean ± SD. ** P < 0.01 (vs. vehicle); n = 5-6 in each group. 
(F) The effect of iron overload on the alteration in p38 and ERK1/2 phosphorylation in 
skeletal muscles after CTX injection. Values are expressed as mean ± SD. *P < 0.05, ** 
P < 0.01 (vs. vehicle at same day); n = 6-10 in each group.  
 
Fig 4. Effect of iron on C2C12 myoblast differentiation  
(A) Effect of iron on cell proliferation and death in C2C12 myoblast cells. Left: 
Myoblast proliferation with or without iron stimulation. Values are expressed as mean ± 
SD, n = 8 in each group. *P < 0.05, **P < 0.01. Right: Myoblast death with or without 
iron stimulation. Values are expressed as mean ± SD, n = 8 in each group. *P < 0.05. 
(B) Western blot images of myogenin, myosin heavy chain (Myh)3, FTH, FTL, and 
tubulin during myoblast differentiation. The changes in protein expression of myogenin 
and Myh3 with or without iron treatment during myoblast differentiation. Values are 
expressed as mean ± SD. *P < 0.05, ** P < 0.01; n = 16 in each group. (C) Effect of 
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iron on fusion index. Left: Representative immunohistochemical fluorescence of Myh3 
(green) and DAPI (blue) in C2C12 myoblast cells. Right: Semi-quantitative analysis of 
fusion index. Values are expressed as mean ± SD. **P < 0.01; n = 7 in each group. (D) 
The effect of iron on the alteration of p38 and ERK1/2 phosphorylation during C2C12 
myoblast differentiation. Values are expressed as mean ± SD. *P < 0.05, **P < 0.01; n 
= 7–8 in each group. 
 
Fig 5. The effect of tempol on iron-mediated suppressive effect on C2C12 myoblast 
differentiation  
(A) Iron content of C2C12 myoblast cells. Values are expressed as mean ± SD. *P < 
0.05, ** P < 0.01; n = 6 in each group. (B) Iron-induced intracellular oxidative stress of 
C2C12 myoblast cells with or without tempol. Values are expressed as mean ± SD. ** P 
< 0.01; n = 12-18 in each group. (C) The effect of tempol on the suppression of muscle 
differentiation induced by iron. Values are expressed as mean ± SD. *P < 0.05, **P < 
0.01 (vs. other 3 groups at same day); n = 12-16 in each group. (D) The effect of tempol 
on iron-mediated suppression of fusion index. Values are expressed as mean ± SD. *P < 
0.05, **P < 0.01; n = 7 in each group. (E) The effect of tempol on iron-mediated 
reduction of p38MAPK and ERK1/2 phosphorylation. Values are expressed as mean ± 
SD. *P < 0.05, **P < 0.01 (vs. Fe+Tempol at same time); n = 8 in each group. (F) 
p38MAPK activity at 0 and 5 min after change in differentiation medium in C2C12 
myoblast cells with or without iron treatment. Values are expressed as mean ± SD. *P < 
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0.05, **P < 0.01; n = 7 in each group. (G) p38MAPK activity at 5 min after change of 
differentiated medium in iron-treated C2C12 myoblast cells with or without tempol. 
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Values are expressed as mean ± SD. n = 5-14 in each group. 
Table 1. Characteristics of vehicle-treated mice and chronic iron-treated mice 
 
Vehicle-treated group  Iron-treated group 
Initial body weight (g) 20.9 ± 1.3 20.9 ± 0.8 
Body weight 4 weeks later (g) 24.9 ± 2.9 24.2 ± 1.5 
Gastrocnemius muscles (mg) 141.2 ± 20.0 136.4 ± 8.9 
Soleus muscles (mg) 9.2 ± 1.2 9.0 ± 1.3 












































Supplementary Figure 1 Ikeda, et al. 



































2M 2Y db/m db/db cont CKD 
Supplementary figure 1 
Protein expression of H-ferritin (FTH) and L-ferritin (FTL) in skeletal muscle of 2-month-old 
and 2-year-old mice, db/m mice and db/db mice, and control mice and CKD mice. Upper 
panel: representative protein expression levels of FTH, FTL, and tubulin. Lower panels: semi-
quantitative densitometry analysis of FTH and FTL expression. Values are expressed as mean 
± SD. *P < 0.05 (vs. 2 months of age, db/m mice, and control mice in each); n = 5 in each 
group. 
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Supplementary figure 2 
The effect of deferoxamine (DFO) on iron-mediated suppression of myoblast differentiation. (A) 
Effect of iron on fusion index. Left: Representative immunohistochemical fluorescence of Myh3 
(green) and DAPI (blue) in C2C12 myoblast cells. Right: Semi-quantitative analysis of fusion index. 
Values are expressed as mean ± SD. *P < 0.05; n = 5 in each group. (B) Western blot images of 
myosin heavy chain (Myh)3, and tubulin during myoblast differentiation. Values are expressed as 
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